Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock Holdings Lifted by California State Teachers Retirement System

California State Teachers Retirement System lifted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 3.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 102,353 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,172 shares during the period. California State Teachers Retirement System owned about 0.16% of Jazz Pharmaceuticals worth $12,325,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Kovack Advisors Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 88.8% during the first quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock worth $6,816,000 after purchasing an additional 26,628 shares during the period. Baupost Group LLC MA increased its position in Jazz Pharmaceuticals by 23.7% during the fourth quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock worth $102,545,000 after acquiring an additional 160,000 shares during the period. Polaris Capital Management LLC increased its position in Jazz Pharmaceuticals by 2.2% during the fourth quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock worth $155,898,000 after acquiring an additional 27,100 shares during the period. John G Ullman & Associates Inc. bought a new stake in Jazz Pharmaceuticals in the 1st quarter valued at $3,631,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $380,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on JAZZ. Wells Fargo & Company lowered their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday. Barclays reduced their target price on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Friday, May 3rd. The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They issued a “buy” rating and a $169.00 target price on the stock. Robert W. Baird reduced their price target on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, Royal Bank of Canada reduced their price target on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating on the stock in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $175.20.

Jazz Pharmaceuticals Stock Down 0.8 %

NASDAQ JAZZ traded down $0.91 during trading hours on Friday, reaching $113.47. 7,987 shares of the company’s stock were exchanged, compared to its average volume of 681,563. The company has a market capitalization of $7.16 billion, a price-to-earnings ratio of 23.58, a price-to-earnings-growth ratio of 1.70 and a beta of 0.58. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $146.70. The company’s 50-day moving average is $107.68 and its two-hundred day moving average is $114.15. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing the consensus estimate of $3.53 by ($1.55). The business had revenue of $901.98 million for the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a return on equity of 28.89% and a net margin of 10.10%. On average, analysts forecast that Jazz Pharmaceuticals plc will post 15.31 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.